Nanoscale synthesis and affinity ranking
Authors:
- 23 April 2018
- journal article
- letter
- Published by Springer Nature in Nature
- Vol. 557 (7704) , 228-232
Abstract
Most drugs are developed through iterative rounds of chemical synthesis and biochemical testing to optimize the affinity of a particular compound for a protein target of therapeutic interest. This process is challenging because candidate molecules must be selected from a chemical space of more than 1060 drug-like possibilities1, and a single reaction used to synthesize each molecule has more than 107 plausible permutations of catalysts, ligands, additives and other parameters2. The merger of a method for high-throughput chemical synthesis with a biochemical assay would facilitate the exploration of this enormous search space and streamline the hunt for new drugs and chemical probes. Miniaturized high-throughput chemical synthesis3,4,5,6,7 has enabled rapid evaluation of reaction space, but so far the merger of such syntheses with bioassays has been achieved with only low-density reaction arrays, which analyse only a handful of analogues prepared under a single reaction condition8,9,10,11,12,13. High-density chemical synthesis approaches that have been coupled to bioassays, including on-bead14, on-surface15, on-DNA16 and mass-encoding technologies17, greatly reduce material requirements, but they require the covalent linkage of substrates to a potentially reactive support, must be performed under high dilution and must operate in a mixture format. These reaction attributes limit the application of transition-metal catalysts, which are easily poisoned by the many functional groups present in a complex mixture, and of transformations for which the kinetics require a high concentration of reactant. Here we couple high-throughput nanomole-scale synthesis with a label-free affinity-selection mass spectrometry bioassay. Each reaction is performed at a 0.1-molar concentration in a discrete well to enable transition-metal catalysis while consuming less than 0.05 milligrams of substrate per reaction. The affinity-selection mass spectrometry bioassay is then used to rank the affinity of the reaction products to target proteins, removing the need for time-intensive reaction purification. This method enables the primary synthesis and testing steps that are critical to the invention of protein inhibitors to be performed rapidly and with minimal consumption of starting materials.Keywords
This publication has 30 references indexed in Scilit:
- Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2013
- Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening PlatformJournal of Medicinal Chemistry, 2013
- Beyond the Numbers: Charting Chemical Reaction SpaceOrganic Process Research & Development, 2013
- Flow chemistry synthesis of zolpidem, alpidem and other GABAAagonists and their biological evaluation through the use of in-line frontal affinity chromatographyChemical Science, 2012
- Design and preparation of new palladium precatalysts for C–C and C–N cross-coupling reactionsChemical Science, 2012
- Mass Spectrometry‐Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery2011
- Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)Journal of Medicinal Chemistry, 2007
- Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK InhibitorsJournal of Medicinal Chemistry, 2007
- A General Technique To Rank Protein−Ligand Binding Affinities and Determine Allosteric versus Direct Binding Site Competition in Compound MixturesJournal of the American Chemical Society, 2004
- An affinity selection–mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial librariesDiscovery of a novel antagonist of E. coli dihydrofolate reductaseInternational Journal of Mass Spectrometry, 2004